T Cell Meeting News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
DRESDEN, Germany, Feb. 3, 2021 /PRNewswire/
GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, today announced interim data from the ongoing Phase I study of their lead asset UniCAR-T-CD123 in relapsed/refractory acute myeloid leukemia (rrAML) at the Virtual 3
rd EHA-EBMT European CAR-T-Cell Meeting, which is held from February 04-06, 2021. The data are being presented as oral presentation by Dr. Martin Wermke, University Hospital Dresden, Germany (February 05, 12:20 CET) and as a poster presentation by Dr. Sabrina Kraus, University Hospital Würzburg, Germany (Abstract 68).
These clinical results present a promising step forward as we continue to evaluate the safety and efficacy of UniCAR-T-CD123, said Professor Gerhard Ehninger, Chief Medical Officer of GEMoaB. We are highly encouraged by the fact that UniCAR-T-CD123 has demonstrated a favorable safety and efficacy ....

Prnewswire Gemoa , Martin Wermke , Sabrina Kraus , Jana Fiebiger , Michael Pehl , Bristol Myers Squibb , Gerhard Ehninger , University Hospital , German Federal Ministry For Education , University Hospital Dresden , T Cell Meeting , Professor Gerhard Ehninger , Chief Medical Officer , Rapidly Switchable Universal , Targeting Module , Acute Leukemia , German Federal Ministry , Affinity Tailored Adaptor , சப்ரினா க்ராஸ் , மைக்கேல் பெல் , பிரிஸ்டல் மைஸ் ஸ்க்விப்ப் , பல்கலைக்கழகம் மருத்துவமனை , ஜெர்மன் கூட்டாட்சியின் அமைச்சகம் க்கு கல்வி , பல்கலைக்கழகம் மருத்துவமனை டிரெஸ்டன் , டி செல் சந்தித்தல் , தலைமை மருத்துவ அதிகாரி ,